Sania Therapeutics presents latest from AAV gene therapy platform at the American Society of Gene & Cell Therapy Annual Meeting
23 Abril 2024 - 7:09AM
Sania Therapeutics presents latest from
AAV gene therapy platform at the American Society of Gene &
Cell Therapy Annual Meeting
Abstracts outline an approach which is
highly translatable, efficacious at low doses and purposefully
designed to be accessible by large patient populations
First indication in spasticity a
blueprint for other prevalent nervous system disorders
LONDON, UK & NEW YORK, USA – 23 April 2024,
Sania Therapeutics (the “Company”), focused on developing targeted
genetic medicines for prevalent disorders, will be sharing the
latest on its adeno-associated viral (AAV) gene therapy approach in
three posters at the American Society of Gene & Cell Therapy
(ASGCT) 2024 Annual Meeting, taking place from 7-11 May 2024 in
Baltimore, MD.
Andy Murray, Ph.D, CEO & Co-Founder
of Sania Therapeutics, said: “Since our official launch
last May, we have been pressing ahead with developing truly
differentiated AAV gene therapies. The three abstracts published
today outline how our human-centric, targeted approach, underpinned
by the R-Scan platform, is helping us reimagine gene therapy, in a
field facing challenges of translatability and safety. We look
forward to providing updates as we develop our first application in
spasticity, as well as exploring how we can harness neural circuits
to treat other disorders.”
Title: Generating human-evolved,
cell-type-specific AAV capsids for targeted gene
deliveryAbstract / Date / Time / Session:
503 / 8 May 2024 / 12:00
pm / AAV Vectors – Capsid EngineeringA
major drawback of the current generation of AAV treatments is that
the tropism of a particular vector can vary from one animal species
to the next, which hinders its translatability. Sania’s approach,
using its R-Scan platform, is focused on generating novel, targeted
vectors that can be successfully and rapidly translated into the
clinic. It combines human induced pluripotent stem cell derived
cell types and microfluidics to perform directed AAV capsid
evolution in an in vitro human system.
In the lead spasticity program, R-Scan has been
used to evolve AAV vectors targeting motor neurons directly via an
intramuscular injection, which show superior transduction of both
human motor neurons in vitro and human neuromuscular organoids. In
addition, the capsids generated by the platform show efficient
transduction of mouse motor neurons following intramuscular
injection, demonstrating translatability from our in vitro system
to whole animal. Work is underway to develop R-Scan to generate
human-evolved vectors for multiple neuronal circuits and cell
types.
Title: Titratable control of neuronal
activity using precision genetic neuromodulationAbstract /
Date / Time / Session: 1606 / 10 May
2024 / 12:00pm / Neurologic
DiseasesMany neurological diseases are linked to the
abnormal electrical activity of specific neural circuits. Gene
therapies could provide a route to targeting these malfunctioning
neural circuits. Sania’s precision therapy for neural circuits
leverages a combination of technology platforms that allow for the
targeted delivery of chemogenetic proteins through engineered AAV
vectors. An investigation was carried out into the efficacy of
SRx-C490, its lead chemogenetic ion channel candidate, and its
impact on modulating excitability in two distinct sub-types of
human induced pluripotent stem cell (iPSC) derived neurons: motor
neurons and sensory neurons.
The AAV-delivered SRx-C490 reduced motor neuron
excitability by 80% and sensory neuron excitability by 75%, whilst
having a minimal impact on baseline activity. This impact on
excitability could be beneficial in a range of neurological
disorders, when combined with Sania’s cell-type specific AAV
capsids.
Title: A low dose, targeted, and
controllable gene therapy for the treatment of
spasticityAbstract / Date / Time / Session:
1140 / 9 May 2024 / 12:00
pm / Neurologic DiseasesSRx-T001 is
Sania’s gene therapy in development for the treatment of
spasticity. It combines an intramuscular injection of AAV gene
therapy with oral medicine to selectively reduce excitability in
targeted motor neurons.
Using a novel AAV vector, Sania has been able to
drive overexpression of a human ion channel selectively in spastic
motor neurons. This overexpression enables it to be susceptible to
low doses of an oral small molecule, which in turn binds to the ion
channel and reduces neuronal excitability.
By combining unique vectors engineered in human
motor neurons, targeted administration, and a novel chemogenetic
system, Sania is developing a gene therapy with a high safety
profile and high specificity, that can be delivered cost
effectively. It also provides a blueprint for future nervous system
disorders.
All three abstracts are available on the ASGCT
website. The posters will be made available on the Sania website
following their presentation.
About Sania Therapeutics Sania
Therapeutics is a ground-breaking biotechnology company pioneering
new approaches for targeted and controllable gene therapies to
treat prevalent disorders. Sania's approach harnesses neural
circuits as a gateway to disease states. Their research and
development is centred around a human-first approach to ultimately
build more translatable, safer and cost-effective AAV gene
therapies capable of treating millions of patients. Sania is based
in London, UK. For more information visit www.saniarx.com.
Sania Therapeutics Andrew Murray |
+4407354836683info@saniarx.com |
ICR ConsiliumMary-Jane ElliottLucy
Featherstone |
+44 (0)20 3709 5700saniatherapeutics@consilium-comms.com |